UTHR - United Therapeutics Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
116.31
+5.34 (+4.81%)
At close: 4:00PM EST

116.31 0.00 (0.00%)
After hours: 4:08PM EST

Stock chart is not supported by your current browser
Previous Close110.97
Open111.04
Bid116.60 x 100
Ask125.00 x 100
Day's Range110.50 - 120.93
52 Week Range100.57 - 152.55
Volume469,883
Avg. Volume353,892
Market Cap5.07B
Beta (3Y Monthly)1.04
PE Ratio (TTM)7.18
EPS (TTM)16.20
Earnings DateOct 23, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est125.64
Trade prices are not sourced from all markets
  • Why Arena Pharmaceuticals Stock Is Soaring Today
    InvestorPlace5 hours ago

    Why Arena Pharmaceuticals Stock Is Soaring Today

    The deal between Arena Pharmaceuticals (NASDAQ:ARNA) and United Therapeutics has to do with the former’s ralinepag. The deal that has Arena Pharmaceuticals stock skyrocketing today is for the exclusive worldwide develop, manufacture and commercialize rights for ralinepag. This has United Therapeutics making an upfront payment of $800 million for those rights.

  • Here's Why Arena Pharmaceuticals Jumped as Much as 30.6% Today
    Motley Fool7 hours ago

    Here's Why Arena Pharmaceuticals Jumped as Much as 30.6% Today

    The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.

  • Reuters10 hours ago

    United Therapeutics to develop, sell Arena Pharma's hypertension treatment

    United Therapeutics Corp on Thursday signed a deal potentially worth up to $1.2 billion for the rights to develop and sell Arena Pharmaceuticals Inc's pulmonary arterial hypertension treatment, ralinepag. The two companies said in a statement the deal for Arena's late-stage experimental treatment also includes milestone payments of up to $400 million based on certain regulatory events. Arena will receive low double-digit tiered royalties on annual net sales of ralinepag, the companies said.

  • Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
    PR Newswire11 hours ago

    Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag

    SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) and United Therapeutics Corporation (UTHR) today announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag.

  • PR Newswire3 days ago

    CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants

    CollPlant (CLGN) today announced the closing of a worldwide exclusive license, development and commercialization agreement with United Therapeutics Corporation (UTHR) for 3D bioprinted lung transplants. As previously announced, CollPlant granted United Therapeutics, through its wholly owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, an exclusive license to its technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants throughout the universe. CollPlant will manufacture and supply BioInk for a few years to meet development process demand, and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk.

  • CNW Group9 days ago

    Correvio Reports Third Quarter 2018 Financial Results

    Correvio Reports Third Quarter 2018 Financial Results

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of UTHR earnings conference call or presentation 31-Oct-18 1:00pm GMT

    Q3 2018 United Therapeutics Corp Earnings Call

  • United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips
    Zacks14 days ago

    United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips

    United Therapeutics (UTHR) beats estimates for both earnings and sales in the third quarter but shares sink 10%.

  • PR Newswire15 days ago

    Nilda Mesa Joins The United Therapeutics Corporation Board Of Directors

    Mesa has had a long and innovative career in environment, energy and sustainability at the city, state, national and global levels, and now writes and presents extensively on climate, energy, equity and urban systems relating to them. From 2012-2014, Mesa served as Director of the New York City Mayor's Office of Sustainability, where she led the pathbreaking OneNYC long term sustainability plan for the city.

  • United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript
    Motley Fool15 days ago

    United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript

    UTHR earnings call for the period ending September 30, 2018.

  • United Therapeutics (UTHR) Q3 Earnings and Revenues Beat Estimates
    Zacks15 days ago

    United Therapeutics (UTHR) Q3 Earnings and Revenues Beat Estimates

    United Therapeutics (UTHR) delivered earnings and revenue surprises of 14.04% and 10.84%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press15 days ago

    United Therapeutics: 3Q Earnings Snapshot

    On a per-share basis, the Silver Spring, Maryland-based company said it had net income of $2.42. Earnings, adjusted for stock option expense and non-recurring costs, were $3.98 per share. The results surpassed ...

  • PR Newswire16 days ago

    United Therapeutics Corporation Reports Third Quarter 2018 Financial Results

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended September 30, ...

  • A Performance Review of JNJ’s Pulmonary Hypertension Business
    Market Realist17 days ago

    A Performance Review of JNJ’s Pulmonary Hypertension Business

    Johnson & Johnson’s (JNJ) pulmonary hypertension business generated revenue of $656.0 million in the third quarter compared to $632.0 million in the third quarter of 2017, reflecting ~3.8% YoY (year-over-year) growth.

  • PR Newswire23 days ago

    United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 24, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its third quarter 2018 financial results ...

  • Simply Wall St.23 days ago

    An Intrinsic Calculation For United Therapeutics Corporation (NASDAQ:UTHR) Shows It’s 45.03% Undervalued

    How far off is United Therapeutics Corporation (NASDAQ:UTHR) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is Read More...

  • PR Newswire25 days ago

    CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants

    NESS ZIONA, Israel and SILVER SPRING, Md., Oct. 22, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN, TASE: CLGN) and United Therapeutics Corporation (UTHR) today announced that they have entered into a license, development and commercialization agreement for 3D bioprinted lung transplants. Under terms of the agreement, CollPlant granted United Therapeutics, through its wholly owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, an exclusive license to its technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants throughout the universe. CollPlant will manufacture and supply BioInk for a few years to meet development process demand, and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk.

  • PR Newswire25 days ago

    CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants

    CollPlant (CLGN) (CLGN.TA) and United Therapeutics Corporation (UTHR) today announced that they have entered into a license, development and commercialization agreement for 3D bioprinted lung transplants. Under terms of the agreement, CollPlant granted United Therapeutics, through its wholly owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, an exclusive license to its technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants throughout the universe. CollPlant will manufacture and supply BioInk for a few years to meet development process demand, and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk.

  • United Therapeutics (UTHR) Q3 Earnings Preview: What's in the Cards?
    Zacks29 days ago

    United Therapeutics (UTHR) Q3 Earnings Preview: What's in the Cards?

    United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Why MannKind Corp. Soared 16.4% Tuesday
    Motley Foollast month

    Why MannKind Corp. Soared 16.4% Tuesday

    The company has completed its planned transaction with United Therapeutics.

  • PR Newswirelast month

    United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement

    RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.  MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

  • GlobeNewswirelast month

    United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement

    United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.  MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

  • AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally
    Zackslast month

    AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally

    AcelRx (ACRX) earns majority votes from an FDA advisory committee, which recommends approval of Dsuvia for treating moderate-to-severe acute pain in adult patients.

  • See what the IHS Markit Score report has to say about United Therapeutics Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about United Therapeutics Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Here's What Sent MannKind Corporation Soaring 66.4% in September
    Motley Foollast month

    Here's What Sent MannKind Corporation Soaring 66.4% in September

    A new collaboration agreement breathed life into the troubled manufacturer of inhaled insulin powder.